A Phase III, Multicenter, Randomized, Study of Atezolizumab Versus Placebo Administered in Combination with Paclitaxel, Carboplatin, and Bevacizumab to Patients with Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Genentech, Inc.
Start Date
January 3, 2018
End Date
December 19, 2022
Administered By
Duke Cancer Institute
Awarded By
Genentech, Inc.
Start Date
January 3, 2018
End Date
December 19, 2022